Ms. Klobuchar (for herself, Mr. Grassley, Mr. Durbin, Mr. Cramer, Mr. Blumenthal, Ms. Ernst, Mr. Welch, Mr. Kelly, and Mr. Booker) introduced the following bill; which was read twice and referred to the Committee on the Judiciary
To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Chuck Grassley
(IA); Richard J. Durbin
(IL); Kevin Cramer
(ND); Richard Blumenthal
(CT); Joni Ernst
(IA); Peter Welch
(VT); Mark Kelly
(AZ); Cory A. Booker
(NJ)
15 U.S.C. 1, 12, 44, 56
and
57c-2 21 U.S.C. 355, 355, 355a, 355f
and
360cc 35 U.S.C. 321note 42 U.S.C. 262
and
262
Document Citations
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. Senate. Preserve Access to Affordable Generics and Biosimilars Act. S. 1096. 119th
Cong., 1st
sess., Introduced in Senate March 24, 2025. https://www.govinfo.gov/app/details/BILLS-119s1096is.
APA
Congress, Senate (2025, March 24). Preserve Access to Affordable Generics and Biosimilars Act (S. 1096 (IS)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119s1096is.
MLA
United States, Congress, Senate. Preserve Access to Affordable Generics and Biosimilars Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119s1096is. 119th Congress, S. 1096, Introduced in Senate 24 Mar. 2025.
Bluebook
S.1096 - 119th Congress (2025-2026): Preserve Access to Affordable Generics and Biosimilars Act, S.1096, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119s1096is.
